Genecast Biotechnology of Beijing acquired exclusive China rights to the Tissue of Origin (TOO) test for difficult-to-identify tumors developed by Cancer Genetics of New Jersey. TOO, a microarray-based gene expression test, analyzes a tumor's genomic ...


ChinaBio® Weekly Update

Contents


Genecast Acquires China Rights to Tumor Test from Cancer Genetics

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Genecast Biotechnology of Beijing acquired exclusive China rights to the Tissue of Origin (TOO) test for difficult-to-identify tumors developed by Cancer Genetics of New Jersey. TOO, a microarray-based gene expression test, analyzes a tumor's genomic information to identify its origin, which helps to classify metastatic, poorly differentiated, or undifferentiated cancers. Founded in 2014, Genecast has developed circulating tumor DNA (ctDNA) detection technology that provides individualized cancer diagnoses. Last year, the company raised $18 million in a Series B round led by Tshinghua Holdings. More details....

Stock Symbol: (NSDQ: CGIX)

Share this with colleagues:

     
 

Ascletis's Second HCV Treatment on Priority Review List in China

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Ascletis Pharma of Hangzhou reported that its second hepatitis C treatment, ravidasvir, has been included in China's list of Proposed Priority Review drugs. Ascletis has submitted an NDA for ravidasvir, a China Category 1 candidate, as part of a two-drug combination treatment, along with already-approved Ganovo®. The combination, an all-oral interferon-free regimen, produced a 99% cure rate in HCV patients after only 12 weeks of treatment in a China Phase II/III trial. Ascletis launched Ganovo three months ago, soon after approval. More details....

Stock Symbol: (HK; 1672)

Share this with colleagues:

     
 

Singlera Reports Positive Results from Blood-based Diagnostic for Colorectal Cancer

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Singlera Genomics, a San Diego-Shanghai diagnostics company, reported its ColonES blood-based colorectal cancer diagnostic showed high sensitivity and specificity in an early China test. In a 1,243 patient study, the ColonES device produced sensitivities of 93% for CRC and 88% for advanced adenomas, with a specificity of 99%. The device is aimed at early diagnosis. Its targeted next-gen sequencing is based on methylation haplotype signatures of circulating tumor methylated DNA (ctmDNA) in blood plasma. More details....

Share this with colleagues:

     
 

Chi-Med Starts China Trials of Syk Inhibitor in Acute Myeloid Leukemia Patients

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Hutchison China MediTech (Chi-Med) has started a China Phase I trial of its novel spleen tyrosine kinase (Syk) inhibitor as a first line treatment in elderly patients with acute myeloid leukemia. The molecule, HMPL-523, will be administered in combination with an approved nucleoside metabolic inhibitor. In September, Chi-Med's lead drug, Elunate® (fruquintinib), was approved in China as a third-line treatment for metastatic colorectal cancer, the first China-developed drug approved for a cancer indication. More details....

Stock Symbol: (AIM/NSDQ: HCM)

Share this with colleagues:

     
 

Alphamab to Start US Phase I Clinical Trial of HER2 Bispecific Antibody

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Suzhou's Alphamab Oncology has received US approval of an IND for KN026, its proprietary HER2 antibody. KN026, the company's lead drug, binds to two separate epitopes on HER2. The candidate started a Phase I China trial earlier this year, and Alphamab said the China trial is proceeding as expected. The company intends to test KN026 in patients with breast, gastric and lung cancer that over-express HER2. One week ago, Alphamab started an initial clinical trial in Australia of its humanized PD-L1/CTLA-4 bispecific antibody. More details....

Share this with colleagues:

     
 

More Recent Articles

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.


 Not a ChinaBio®Today Subscriber?

Here's what you get with a paid subscription to ChinaBio® Today:
  • Website access to all current articles and commentary
  • Full access to over 2000 archived articles on the biotech industry

Greg B. Scott
Executive Editor
ChinaBio® Today


ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC


Safely Unsubscribe ArchivesPreferencesContactSubscribePrivacy